OliX Pharmaceuticals has announced the start of a Phase 1 clinical trial for its RNAi therapeutic, OLX72021, which is being developed to treat male-pattern baldness. The study will assess the drug's safety, tolerability and pharmacokinetics in single intradermal injections in up to 30 healthy males with androgenic alopecia over an eight-week period. Participants will be split into five cohorts and receive different dosages or placebos in six areas of alopecia near the crown area. OLX72021 works by suppressing hormone activity that causes androgenic alopecia by reducing the expression of the androgen receptor. OliX acquired a US patent for OLX72021 last year.